Author: Lima-MartÃnez, Marcos M.; Carrera Boada, Carlos; Madera-Silva, Marialaura D.; MarÃn, Waleskha; Contreras, Miguel
Title: COVID-19 and diabetes: A bidirectional relationship Cord-id: ih34tkmx Document date: 2021_4_24
ID: ih34tkmx
Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19). Diabetes is one of the most frequent comorbidities in people with COVID-19 with a prevalence that varies between 7 and 30%. Diabetics infected with SARS-CoV-2 have a higher rate of hospital admission, severe pneumonia, and higher mortality compared to non-diabetic subjects. Chronic hyperglycemia can compromise innate and humoral immunity. Furthermore, diabetes is associated wi
Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19). Diabetes is one of the most frequent comorbidities in people with COVID-19 with a prevalence that varies between 7 and 30%. Diabetics infected with SARS-CoV-2 have a higher rate of hospital admission, severe pneumonia, and higher mortality compared to non-diabetic subjects. Chronic hyperglycemia can compromise innate and humoral immunity. Furthermore, diabetes is associated with a low-grade chronic inflammatory state that favors the development of an exaggerated inflammatory response and therefore the appearance of acute respiratory distress syndrome. Recent evidence has shown that SARS-CoV-2 is also capable of causing direct damage to the pancreas that could worsen hyperglycemia and even induce the onset of diabetes in previously non-diabetic subjects. Therapeutic strategies should be aimed at facilitating patient access to the healthcare system. Control of blood glucose and comorbidities must be individualized in order to reduce the incidence of complications and decrease the burden on health systems. In this article we will review the pathophysiological mechanisms that explain the bidirectional relationship between COVID-19 and diabetes mellitus, its implication in the prognosis and management of hyperglycemia in this group of patients.
Search related documents:
Co phrase search for related documents- ace enzyme and acute dysfunction: 1, 2
- ace enzyme and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace enzyme and low molecular weight heparin: 1
- ace enzyme convert and acute respiratory syndrome: 1
- ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
- ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace inhibitor and low molecular weight heparin: 1
- active bleeding and acute ards respiratory distress syndrome: 1, 2
- active bleeding and acute dysfunction: 1
- active bleeding and acute respiratory syndrome: 1, 2
- active bleeding and low molecular weight heparin: 1, 2, 3
- acute ards respiratory distress syndrome and low grade inflammatory: 1
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute dysfunction and low molecular weight heparin: 1
- acute hyperglycaemia and low grade inflammatory: 1
- acute hyperglycaemia and low grade inflammatory status: 1
- acute respiratory syndrome and low grade inflammatory: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low molecular weight heparin prophylactic dose: 1, 2
Co phrase search for related documents, hyperlinks ordered by date